News

Most recently, Mr Mathias has served as vice president of marketing and business development at Alimentary Health, a biotechnology company. Prior to Alimentary Health, Mr Mathias was director

According to Dendreon, the magnitude of the survival difference observed in the intent to treat population resulted in the study successfully achieving the pre-specified level of statistical significance

The FDA has 30 days to review Tekmira’s investigational new drug (IND) application and to request any additional information before allowing the clinical trial to proceed. Tekmira will

Nanobac Pharmaceuticals, a research-based, bio-lifescience company, and Eureka Genomics, a provider of next generation sequencing, have signed a definitive merger agreement, which delineates the terms and conditions under

In addition, the company announced that James Lock will not stand for re-election as a director on the company’s board of directors. Mr Lock will continue to work

Oxycyte will be manufactured at Hospira’s Clayton, North Carolina, facility which specializes in emulsion technology. Hospira will formulate, fill, finish and label Oxycyte to meet clinical good manufacturing

According to Cerus, the Intercept blood system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of known and emerging pathogens, including viruses,

The Phase Ib open-label, dose-escalating study will enroll up to 30 patients diagnosed with IgA nephropathy at clinical sites in Canada. The trial design utilizes a continuous reassessment

The collaboration will deploy Ensemble’s proprietary drug discovery platforms and Ensemblin collections to discover and advance drug candidates. Bristol-Myers Squibb will have the right to develop and commercialize